Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial

Arsenic trioxide (ATO) is synergistic with ascorbic acid (AA) and melphalan against myeloma both in vitro and in vivo. The aim of this randomized phase II trial was to determine the safety and efficacy of a combination of ATO, melphalan, and AA as preparative regimen in 48 patients undergoing autolo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Qazilbash, Muzaffar H., Saliba, Rima M., Nieto, Yago, Parikh, Gaurav, Pelosini, Matteo, Khan, Fatima B., Jones, Roy B., Hosing, Chitra, Mendoza, Floralyn, Weber, Donna M., Wang, Michael, Popat, Uday, Alousi, Amin, Anderlini, Paolo, Champlin, Richard E., Giralt, Sergio
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4112362/
https://ncbi.nlm.nih.gov/pubmed/19041063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2008.09.019
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires